Structure and Mechanisms of LINE-1: an Emerging Biomarker & Cancer Target
Martin Taylor, M.D., Ph.D., Instructor
Dr Taylor received his M.D. and Ph.D. from Johns Hopkins University where he studied the role of ghrelin acylation in control of metabolism and its potential as a therapeutic target. He then went on to study the interactions between the LINE-1 transposon and host and the role of LINE-1 in cancer in Boeke and Burns labs. He completed residency in Anatomic Pathology (AP) at Massachusetts General Hospital, where he served as Chief Resident and completed subspecialty training in gastrointestinal (GI) pathology. Thereafter, he began postdoctoral training at the Whitehead Institute / MIT. He joined the faculty of Harvard Medical School as Instructor in Pathology in 2021 and practices clinically as a GI pathologist. Marty has just set up his lab in Brown – Martin S. Taylor, MD, PhD | Pathology and Laboratory Medicine | Medical School | Brown University
Current research: Marty is studying the structure and function of the LINE-1 ORF2 protein, and the potential utility of LINE-1 ORF1p as a cancer biomarker in tissue and plasma.
Marty’s career development and research on mTORC2 activation and substrate recognition in growth factor signaling are supported by a K08 award from NIH.
Date: 7 November 2024, 13:00 (Thursday, 4th week, Michaelmas 2024)
Venue: Old Road Campus Research Building, Headington OX3 7DQ
Venue Details: Rooms 71 a/b/c (Ground floor)
Speaker: Dr Martin Taylor (Brown University, Harvard Medical School, and Massachusetts General Hospital)
Organising department: Department of Oncology
Organiser: Yuliia Karpenko
Organiser contact email address: adminsupport@oncology.ox.ac.uk
Host: Associate Professor Eileen Parkes (University of Oxford)
Booking required?: Not required
Audience: Members of the University only
Editor: Yuliia Karpenko